Rectal

URCC 19075 **MBMC ONLY** (Temporarily Closed to Enrollment)

Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)

---

ECOG-ACRIN EA2201 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)

A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma

---

A222004 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

---

URCC-21038

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

---

NSABP C-14 / CORRECT-MRD II

Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease

---

A221805 **EFFECTIVE 3/31/23, at 7am CST, the Phase II portion of the study will permanently close to new patient accrual. Information regarding the status of the Phase III component will be sent upon completion of the Phase II analyses. If the analysis is positive, a reactivation notice will be distributed at the time A221805 opens to Phase III enrollment.**

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

---

WF 1806

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study

---

URCC 18007

Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue

---